Options for empagliflozin in combination therapy in type 2 diabetes mellitus
about
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
P2860
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@ast
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@en
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@nl
type
label
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@ast
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@en
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@nl
prefLabel
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@ast
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@en
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@nl
P2860
P3181
P356
P1476
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
@en
P2093
Kenneth S Hershon
P2860
P304
P3181
P356
10.2147/IJGM.S100288
P407
P577
2016-01-01T00:00:00Z